Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply
Aliment Pharmacol Ther
.
2022 Feb;55(4):485-486.
doi: 10.1111/apt.16762.
Authors
Rifaat Safadi
1
,
Marius Braun
2
,
Adi Francis
3
,
Yael Milgrom
1
,
Muhammad Massarwa
1
,
David Hakimian
1
,
Wadi Hazou
1
,
Assaf Issachar
2
,
Zivit Harpaz
4
,
Motti Farbstein
4
,
Inbal Itzhak
4
,
Naama Lev-Cohain
5
,
Avital Bareket-Samish
6
,
Michael H Silverman
4
,
Pnina Fishman
4
Affiliations
1
The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
2
The Liver Institute, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel.
3
Cardiology Department, Holy Family Hospital, Nazareth, Israel.
4
Can-Fite BioPharma Ltd, Petah-Tikva, Israel.
5
The Radiology Dep. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
6
BioInsight Ltd, Binyamina, Israel.
PMID:
35092054
DOI:
10.1111/apt.16762
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Inflammation / drug therapy
Non-alcoholic Fatty Liver Disease* / drug therapy